Seres Therapeutics Announces First Patient Enrolled In Phase 1b Study Of SER-155 Investigational Microbiome Therapeutic To Reduce The Risk Of Antibiotic-Resistant Bacterial Infections And Graft-Versus-Host Disease

by Yogesh Tanwar | Nov 30, 2021 | Extra Jobs | 0 comments

Submit a Comment Cancel reply

Your email address will not be published. Required fields are marked *

Comment *

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.